+27 11 049 4200 info@avacarehealth.com


We offer research and development in biologics, chemotherapeutics, clinical medicine and diagnostics.





Afrigen Biologics (Pty) Ltd was founded in 2014 with the initial goal of establishing local production capacity and capabilities for a tuberculosis (TB) vaccine, in collaboration with IDRI and the South African vaccine company Biovac.

This mission subsequently expanded to encompass the establishment of a diversified, multi-platform, and multi-product company in South Africa. A core platform in Afrigen focuses on adjuvant formulation, which led to the establishment of the first Adjuvant Formulation Centre in Africa.

The success of the adjuvant platform also prompted innovative applications in the realm of health supplements, complementary vitamins, minerals, nutraceuticals, and pharmaceutical products.

In 2021, a significant milestone was achieved when Afrigen was selected by the World Health Organization (WHO) and its partners to serve as the Global mRNA Technology Hub for Low- and Middle-Income Countries (LMICs). This designation solidified Afrigen’s strategic intent and positioned the company to have a substantial impact in this domain.

Afrigen plays a central role within a network of 15 companies across 15 Low- and Middle-Income Countries. This network is focused on establishing vaccine manufacturing capacity and capabilities, with the overarching goals of ensuring vaccine security and enhancing pandemic preparedness.


In 2021, Afrigen entered into a contract with the World Health Organization (WHO) and the Medicines Patent Pool (MPP) under the ACT-A COVAX initiative. This contract designates Afrigen as the mRNA vaccine technology transfer and training Hub for Low- and Middle-Income Countries (LMICs).

Collaborating with partners, Afrigen is in the process of developing an mRNA vaccine production and innovation platform, which has been validated through the creation of the first mRNA SARS-Covid19 vaccine in Africa.

This innovative multi-product platform is slated to be transferred to 15 to 20 companies in LMICs as part of the WHO and mRNA Hub program.


Afrigen is the only adjuvant and nanotech formulation laboratory on the continent. This unique biotech start-up boasts seven PhDs, four MScs and two engineers dedicated to next-generation adjuvants for increased safety and efficacy of human and animal vaccines. A first for Africa, the Afrigen platform recently launched Nanosomal CBD+, a superior bioavailable CBD.